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Background/Aims: Epigallocatechin-3-gallate (EGCG), the 
primary catechin in green tea, has anti-inflammatory and 
anti-oxidative properties. The aim of the current study was 
to characterize the impact of EGCG on lipopolysaccharide 
(LPS)-induced innate signaling in bone marrow-derived mac-
rophages (BMMs) isolated from ICR mice. Methods: The ef-
fect of EGCG on LPS-induced pro-inﬂ  ammatory gene expres-
sion and nuclear factor-κB (NF-κB) and mitogen-activated 
protein kinase (MAPK) signaling was examined using reverse 
transcription-polymerase chain reaction, Western blotting, 
immunoﬂ  uorescence, and the electrophoretic mobility shift 
assay. Results: EGCG inhibited accumulation of LPS-induced 
IL-12p40, IL-6, MCP-1, ICAM-1, and VCAM-1 mRNA in BMMs. 
EGCG blocked LPS-induced IκBα degradation and RelA 
nuclear translocation. EGCG blocked the DNA-binding activ-
ity of NF-κB. LPS-induced phosphorylation of ERK1/2, JNK, 
and p38 was inhibited by EGCG. U0126 (an inhibitor of MEK-
1/2) suppressed the LPS-induced IL-12p40, IL-6, MCP-1, 
ICAM-1, and VCAM-1 mRNA accumulation in BMMs. Conclu-
sions: These results indicate that EGCG may prevent LPS-
induced pro-inﬂ  ammatory gene expression through blocking 
NF-κB and MAPK signaling pathways in BMMs. (Gut Liver 
2012;6:188-196)
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INTRODUCTION
Complementary and alternative medicine such as herbal/
dietary therapy is becoming an increasingly attractive approach 
to the treatment and prevention of various inflammatory disor-
ders, including inflammatory bowel disease (IBD).
1,2 However, 
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despite their clear popularity, absence of empirical data showing 
efficacy and mechanisms of action in vivo prevents their incor-
poration into mainstream medicine. 
Green tea is one of the widely consumed beverages in the 
world. Many epidemiologic studies showed that green tea con-
sumption has beneficial effects in preventing the development 
of atherosclerosis and prostatic cancer. It is generally agreed 
that these beneficial effects of green tea are mediated by its 
polyphenols. Green tea contains four polyphenolic compounds 
known as catechin; (-)-epicatechin, (-)-epigallocatechin, (-)-epi-
catechin gallate and (-)-epigallocatechin-3-gallate (EGCG). 
EGCG is the most abundant polyphenol in green tea, and has a 
variety of modulatory actions on physiological functions, such 
as anti-inflammatory, anti-oxidative, anti-mutagenic, and anti-
carcinogenic effects.
3-7 
IBD, such as Crohn’s disease and ulcerative colitis, is a chron-
ic and relapsing intestinal inflammation of unknown etiology. 
It has been proposed that IBD is caused by from aberrant mu-
cosal immune responses to nonpathogenic bacteria and bacte-
rial products in the intestine.
8-11 In IBD, the intestinal epithelial 
cell damage results in an increased uptake of luminal antigens, 
including bacteria and bacterial products, and thus leads to the 
activation of immune cells in lamina propria and the mounting 
of inflammatory responses. Among the immune cells, macro-
phages and monocytes play an important role in the initiation, 
development and outcome of immune response and are also 
found in the inflamed gut mucosa.
12-15 However, until now, the 
direct effects of EGCG on bone marrow-derived macrophages 
(BMMs) in intestinal inflammation have not been fully investi-
gated.
Lipopolysaccharide (LPS), a gram negative bacteria-derived 
cell wall product, stimulates over-production of nitric oxide, 
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cells.
16,17 Inflammatory cytokines are important pro-inflam-
matory mediators and may be responsible for the induction 
of chemokines, enzymes and adhesion molecules in intestinal 
inflammation. Most inflammatory cytokines are induced by 
the activation of transcription factors and protein kinases such 
as the transcriptional nuclear factor-κB (NF-κB) and mitogen-
activated protein kinase (MAPK).
18-22 Mucosal inflammation in 
patients with IBD and in experimental models of intestinal in-
flammation is accompanied by elevated levels of activated NF-
κB.
23-26 It has been shown previously that MAPK plays a critical 
role in the transduction of inflammatory response in variable 
cell types. MAPK differentially regulates the production of pro- 
and anti-inflammatory cytokines in immune cells including 
dendritic cells.
27-30
In the present study, we investigated the impact of EGCG on 
LPS-induced innate signaling and proinflammatory gene ex-
pression in BMMs.
MATERIALS AND METHODS
1. Isolation and culture of BMMs
Bone marrow cells were isolated from 5- to 8-week-old 
ICR mice (Samtako Science, Daejeon, Korea) as previously de-
scribed.
31 Mice were sacrificed by cervical dislocation. Femora 
and tibiae were aseptically removed and dissected free of adher-
ent soft tissue. The bone ends were cut, and the marrow cavity 
was flushed out into a petri dish by slowly injecting MEM-α 
medium (Hyclone, Logan, UT, USA) at one end of the bone us-
ing a sterile 21-gauge needle. The bone marrow suspension 
was carefully agitated with a plastic Pasteur pipette to obtain 
a single cell suspension. Bone marrow cells were washed and 
depleted of red blood cell (RBC) by hypotonic lysis using RBC 
lysing buffer (Sigma-Aldrich, St. Louis, MO, USA). After wash-
ing twice with phosphate-buffered saline (PBS), the cells were 
suspended in MEM-α medium supplemented with 10% FBS and 
50 units/mL penicillin, 50 μg/mL streptomycin (Gibco, Grand Is-
land, NY, USA). The number of viable cells was determined with 
trypan blue (Gibco) and bone marrow cells were cultured on 10 
cm
2 tissue culture dishes in total amount of 2×10
6 cells/dish. 
10 ng/mL of mouse macrophage colony stimulating factor (M-
CSF; BioSource, Camarillo, CA, USA) was added to every 10 cm 
dish to differentiate BMMs. On day 3, non-adherent cells were 
discarded and adherent cells (immature BMMs) were suspended 
in fresh MEM-α with M-CSF and used in subsequent experi-
ment. All of the cells were cultured at 37
oC under a humidi-
fied atmosphere containing 5% CO2. EGCG was obtained from 
Sigma-Aldrich and stored as 50 mM stock solutions in 4
oC. LPS 
from Escherichia coli (serotype 0111:B4) was also purchased 
from Sigma-Aldrich and dissolved in sterile, pyrogen free PBS. 
U0126 (a specific inhibitor of MEK-1/2, an upstream effector of 
ERK1/2) was obtained from Calbiochem (San Diego, CA, USA). 
Cells were pretreated with various concentrations of EGCG (0-
100 μM) or U0126 (20 μM) after which they were stimulated 
with LPS (0.5-1 μg/mL) for times indicated (0 to 1 hour). All 
methods used in this study was approved by the Animal Care 
and Use Committee at the Chonnam National University Medi-
cal School Research Institution and conformed to US National 
Institutes of Health (NIH publication No. 86-23 revised 1985) 
guidelines.
2. Cell viability
BMMs were plated to a 96-well plate at a density of 1×10
4 
cells/well and incubated in medium with various concentrations 
of EGCG and LPS. After incubation for 24 hours, cell viability 
was determined by EZ-CyTox (tetrazolium salts, WST-1) cell 
viability Assay kit (Daeil Lab Inc., Seoul, Korea). After WST-
1 reagent was added for 1 to 2 hours at 37
oC, the absorbance 
was determined using a microplate reader (Infinite M200; Tecan 
Austria GmbH, Grödig, Austria) with Magellan V6 data analysis 
software (Tecan, Austria GmbH, Austria). Triplicate wells were 
used for each experimental condition and all experiments were 
repeated at least three times.
3. Western blotting
The cells were exposed to LPS (1 μg/mL) in the absence or 
presence of 100 μM EGCG-pretreatment. Following 10 or 30 
minutes of incubation at 37
oC, cells were washed twice with 
cold PBS and lysed with RIPA buffer (1 M Tris-HCl, 150 mM 
NaCl, 1% Triton X-100, 2 mM EDTA) with 1 mM PMSF, Halt
TM 
Phosphatase inhibitor and Halt
TM Protease inhibitor cocktail 
(Thermo) for 15 minutes at 4
oC. Lysates were cleared by cen-
trifugation at 14,000 g for 20 minutes at 4
oC. The protein con-
centrations of cell lysates were determined using BCA
TM protein 
assay (Thermo, Rockford, IL, USA). Equivalent amounts of pro-
teins were separated by 12% SDS-PAGE and electrophoretically 
transferred to PVDF membrane (Millipore, Billerica, MA, USA). 
The analysis was used primary antibodies as described by the 
manufacturer; polyclonal anti-IκBα, phospho-IκBα, ERK1/2, 
phospho-ERK1/2, JNK, phospho-JNK, p38, phospho-p38 (Cell 
signaling, Danvers, MA, USA), polyclonal anti-GAPDH (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA). After washing three 
times with TBST, membranes were incubated with secondary 
HRP-conjugated anti-mouse IgG for 1 hour. After washing, the 
blots were detected with chemiluminescence (ECL) HRP sub-
strate (Millipore) by image reader (Ras-4000; Fujifilm, Tokyo, 
Japan).
4. Real-time reverse transcription-polymerase chain reac-
tion (RT-PCR)
Total RNA was isolated using the Trizol reagent (Invitrogen, 
Carlsbad, CA, USA) following the instructions provided by the 
manufacturer. The quantity and purity of total RNA were deter-
mined by measuring the optical density using Nanodrop (Nano-
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with 1 μg total RNA using MMLV reverse transcriptase (Invit-
rogen) and RNAsin (Takara, Otsu, Shiga, Japan) for first strand 
cDNA synthesis. PCR amplification of cDNA was performed 
using gene-specific primers (Table 1). The quantitative real-time 
PCR reactions were performed using SYBR Green (SensiMixplus 
SYBR; Quantace, London, UK) on a Rotor-GeneTm 6000 real-
time rotary analyzer (Corbett, San Francisco, CA, USA). The 
regular PCR was done by using Go taq. Polymerase (Promega, 
Madison, WI, USA).
5. Immunoﬂ  uoroscence
The cells were plated on 8-chamber slide (Nunc, Rochester, 
NY, USA). The cells were exposed to LPS (1 μg/mL) for 10 min-
utes in the absence or presence of 100 μM EGCG-pretreatment. 
Then cells were washed with PBS and fixed with 4% formalde-
hyde in room temperature. Next, cells were permeabilized using 
PBS containing 0.25% Triton X-100 and blocked with PBS con-
taining 1% BSA and 10% FBS. Cells were subjected to staining 
with polyclonal anti-p65 antibody (Santa Cruz Biotechnology) 
overnight at 4
oC. RelA (p65) in cells was visualized with Alexa 
488 (green) conjugated secondary antibody (Invitrogen). Cover-
slips were mounted in ProLong Gold antifade reagent contain-
ing DAPI (Invitrogen) and analyzed using fluorescent micros-
copy.
6. Electrophoretic mobility shift assay (EMSA)
Nuclear proteins were prepared following the previously 
described.
32 The treated cells were washed twice with PBS and 
resuspended in lysis buffer (10 mM HEPES [pH7.9], 0.5 mM KCl, 
1.5 mM MgCl2, 0.5 mM DTT, 0.2 mM PMSF, 0.1% NP40). Cells 
were left on ice for 5 minutes and centrifuged at 12,000×g for 5 
minutes. Resulting pellet was resuspended in high salt buffer (20 
mM HEPES [pH 7.9], 25% Glycerol, 1.5 mM MgCl2, 0.8 M KCl, 
0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF) and centrifuged at 
12,000×g for 20 minutes. The supernatant was collected as the 
nuclear extract and protein concentration was estimated using 
BCA
TM protein assay (Thermo). The nuclear extracts were stored 
at -70
oC. EMSA was performed using the LightShift
TM Chemilu-
minescent EMSA kit (Pierce, Rockford, IL, USA) according to the 
manufacturer’s instructions. The reaction mixtures (10 μL) con-
taining about 5 μg nuclear extracts were incubated with 10 fmol 
of the biotin-labeled double-stranded oligonucleotide probes 
(NF-κB/p65 oligonucleotides; 5’-CAT CGG AAA TTT CCG GAA 
ATT TCC GGA AAT TTC CGG C-3’/5’-GCC GGA AAT TTC TGG 
AAA TTT CCG GAA ATT TCC AT G-3’) in reaction buffer for 20 
minutes at room temperature. Samples were then run into a 5% 
nondenaturing polyacrylamide gel and transferred to Biodyne
TM 
B Nylon membrane (Thermo, Rockford, IL, USA) in 0.5×TBE 
buffer. The biotin-labeled NF-κB/p65 probe was detected with a 
using the streptavidin-horseradish peroxidase conjugate and the 
chemiluminescent substrate. 
7. Statistical analysis
For in vitro experiments, data were analyzed using a paired 
Student’s t-test and differences were considered significant if 
2-tailed p-values were <0.05.
RESULTS
1. Impact of EGCG on the viability of BMMs
In order to study the effect of EGCG on cell viability, cells 
were exposed to different concentrations of EGCG (0 to 200 
μM) or LPS (0.5 to 1 μg/mL) for 24 hours. EGCG treatment or 
LPS stimulation did not affect cell viability in BMMs (data not 
shown).
2. EGCG inhibits LPS-induced proinflammatory gene ex-
pressions in BMMs
To examine whether EGCG could inhibit the LPS-induced 
inflammatory cytokines, chemokines and adhesion molecules 
expression in BMMs, mRNA levels of LPS-induced inflamma-
tory cytokines, chemokines, and adhesion molecules was mea-
sured by RT-PCR. LPS-induced IL-12p40, IL-6, MCP-1, ICAM-1 
and VCAM-1 mRNA accumulations in BMMs were inhibited by 
EGCG treatment (Fig. 1). 
3. EGCG inhibits LPS-induced IκBα phosphorylation/degra-
dation and RelA nuclear translocation in BMMs 
To determine whether inhibition of LPS-induced NF-κB acti-
vation was due to reduced IκBα phosphorylation/degradation, 
cells were pretreated with EGCG for 1 hour, before exposing 
them to 1 μg/mL LPS for 30 minutes. In Western blotting, EGCG 
treatment inhibited LPS-induced IκBα phosphorylation/degra-
dation (Fig. 2A). The nuclear translocation of NF-κB followed 
Table 1. Primers for Reverse Transcription-Polymerase Chain Reaction
Primers Forward/Reverse
L-12p40 5'-CCAGCTTCTTCATCAGGGAC-3'/5'-GTCCCTGATGAAGAAGCTGG-3'
IL-6 5’-GGATACCACCCACAACAGACC-3’/5’-AATCAGAATTGCCATTGCAC-3’
MCP-1 5'-GAAGACCTTAGGGCAGATGCAG-3'/5'-GTAGCAGCAGGTGAGTGGGG-3'
ICAM-1 5'-GACCCCAAGGAGATCACATTC-3'/5'-GAAGATCGAAAGTCCGGA-3’
VCAM-1 5'-CTGTGGGTGTTGAGGATGAGC-3'/5'-TCTCCCGTGTACAAGTGGTCC-3'
GAPDH 5'-ACCACAGTCCATGCCATCAC-3'/5'-TCCACCACCCTGTTGCTGTA-3'Joo SY, et al: The Impact of EGCG on LPS-Induced Innate Signaling  191
IκBα degradation. RelA (p65) nuclear translocation was evalu-
ated by immunfluorescence. RelA nuclear translocation was 
blocked by EGCG treatment (Fig. 2B).
4. EGCG inhibits NF-κB-DNA binding activity in BMM
The DNA binding activity of NF-κB was evaluated by EMSA. 
BMMs were pretreated with EGCG (100 μM) for 1 hour and then 
stimulated with LPS (1 μg/mL) for 30 minutes. EGCG markedly 
suppressed the binding of nuclear extracts to NF-κB consensus 
nucleotide in BMMs (Fig. 3).
5.   EGCG inhibits LPS-induced phosphorylation of MAPK 
signal proteins in BMMs
MAPK is a critical factor mediating inflammatory responses 
Fig. 1. Epigallocatechin-3-gallate (EGCG) inhibited the lipopolysac-
charide (LPS)-induced pro-inflammatory gene expression in bone 
marrow-derived macrophages (BMMs). The BMMs were pretreated 
with EGCG (100 μM) for 1 hour, stimulated with LPS (1 μg/mL) and 
harvested at 1 hour. RNA was isolated using the TRIzol procedure, 
and 1 μg of total RNA was reverse transcribed and amplified using 
primers for IL-12p40, IL-6, MCP-1, ICAM-1, VCAM-1, and GAPDH. 
*p<0.05, 
†p<0.005 compared to unstimulated cells; 
‡p<0.05, 
§p<0.005 
compared to LPS stimulation.192  Gut and Liver, Vol. 6, No. 2, April 2012
to external stimuli such as LPS. We next examined whether 
EGCG suppress MAPK signaling pathway in the presence of 
LPS by studying the phosphorylation level of MAPK signaling 
proteins in BMMs. Western blot analysis showed that EGCG in-
hibited LPS-induced phosphorylations of ERK1/2, JNK, and p38 
in BMMs (Fig. 4). 
6. Effect of MAPK inhibitor on LPS-induced proinflamma-
tory gene expression in BMMs
U0126 (a specific inhibitor of MEK-1/2, an upstream effec-
tor of ERK1/2) and EGCG suppressed the LPS-induced ERK1/2 
phosphorylation and IL-12p40, IL-6, MCP-1, ICAM-1, and 
VCAM-1 mRNA accumulations in BMMs (Fig. 5). 
DISCUSSION
IBD appears to result from dysregulated immune response to 
various external stimuli.
8-11 Current therapies for patients with 
IBD are largely based on immunosuppressants such as predni-
sone, azathioprine and 6-mercaptopurine or biologics such as 
infliximab.
8-11 Although these are relatively effective, a number 
of patients develop significant side effects and/or become un-
responsive to them. Recent data demonstrate that many plant-
derived compounds show anti-inflammatory activities and 
most of their actions are related to cytokines, chemokines or 
adhesion molecules. Many inflammatory disorders are initially 
associated with an imbalance of cytokine networks. Therefore, 
complementary and alternative medicine including plant de-
rived agents would be useful for the treatment of inflammatory 
disorders including IBD.
33 Practically, IBD patients commonly 
use complementary and alternative medicine in addition to tra-
ditional therapy. 
Green tea is one of the most popular beverages worldwide 
and believed to elicit anti-oxidant, anti-carcinogenic, anti-
Fig. 2. Epigallocatechin-3-gallate 
(EGCG) inhibited lipopolysaccharide 
(LPS)-induced IκBα phosphoryla-
tion/degradation and RelA nuclear 
translocation in bone marrow-de-
rived macrophages (BMMs). (A) The 
BMMs were pretreated for 1 hour 
with EGCG (100 μM) and stimulated 
with LPS (1 μg/mL) for 10 and 30 
minutes. Total protein was extracted, 
and 20 μg of protein was subjected 
to SDS-PAGE followed by IκBα and 
β-tubulin immunoblotting using the 
ECL technique. (B) The BMMs were 
pretreated with EGCG (100 μM) for 1 
hour and stimulated with LPS (1 μg/
mL) for 30 minutes. RelA localiza-
tion was visualized using an anti-
RelA primary antibody followed by 
a rhodamine-conjugated detection 
antibody. Joo SY, et al: The Impact of EGCG on LPS-Induced Innate Signaling  193
inflammatory and immunomodulatory properties. EGCG is the 
most abundant polyphenol present in green tea and is believed 
to provide the majority of these beneficial effects observed with 
green tea consumption.
3-7 Although these beneficial effects of 
EGCG on inflammation and cancer have been studied exten-
sively in various cell types, the scientific basis for these benefi-
cial effects of EGCG is still lacking.
A prominent feature of IBD is the presence of inflammatory 
cells in the gut mucosa, and neutrophil migration depends on 
cytokines released by macrophages and mast cells. Especially, 
mucosal macrophages derived from circulating monocytes play 
a major role in chronic mucosal inflammation.
12-15 Therefore, the 
aim of current study was to characterize the impact of EGCG on 
LPS-induced innate signaling in BMMs. 
Cell signaling pathways that are responsible for maintaining a 
bal  ance between cell proliferation and apoptosis, have emerged 
as rational targets for the management of inflammation and 
cancer.
7 IBD is known to have alterations in multiple cellular 
signaling pathways and because of the complexities in the in-
teraction among multiple signaling networks, definite treatment 
and cure for IBD are still elusive. 
NF-κB is a mammalian transcription factor that regulates the 
expression of genes encoding proinflammatory cytokines, che-
mokines, immune receptors and adhesion molecules that play 
a key part in inflammation related injury such as IBD.
18-20 In 
Fig. 3. Epigallocatechin-3-gallate (EGCG) inhibited nuclear factor-κB 
(NF-κB)-DNA binding activity in bone marrow-derived macrophages 
(BMMs). The DNA-binding activity of NF-κB was evaluated by 
EMSA. The BMMs were pretreated with EGCG (100 μM) for 1 hour, 
stimulated with LPS (1 μg/mL) for 30 minutes, and nuclear extracts 
were prepared.
Fig. 4. Epigallocatechin-3-gallate (EGCG) inhibited the lipopolysac-
charide (LPS)-induced phosphorylation of MAPK signaling proteins 
in bone marrow-derived macrophages (BMMs). The BMMs were 
pretreated for 1 hour with EGCG (100 μM) and stimulated with LPS 
(1 μg/mL) for 30 minutes. Total protein was extracted, and 20 μg of 
protein was subjected to SDS-PAGE followed by phospho-ERK1/2, 
total ERK1/2, phospho-JNK, total JNK, phospho-p38, total p38, 
and β-tubulin immunoblotting using the chemiluminescence (ECL) 
technique. The results are representative of three independent experi-
ments.
Fig. 5. The effect of a MAPK inhibitor on the lipopolysaccharide 
(LPS)-induced gene expression in bone marrow-derived macrophages 
(BMMs). The BMMs were pretreated with 20 μM U0126 and 100 μM 
epigallocatechin-3-gallate (EGCG) for 1 hour and stimulated with 1 
μg/mL LPS for 1 hour. U0126 and EGCG suppressed LPS-induced 
ERK1/2 phosphorylation (A), and IL-12p40, IL-6, MCP-1, ICAM-1 
and VCAM-1 accumulation of mRNA (B) in BMMs.194  Gut and Liver, Vol. 6, No. 2, April 2012
unstimulated cells, NF-κB, a predominant heterodimer consist-
ing of p65 (RelA) and p50 subunits, is present as a latent, inac-
tive, IκB bound complex in the cytoplasm but upon activation 
by various external stimuli, NF-κB rapidly translocates to the 
nucleus, binds to specific sequences in the promoter region and 
induces proinflammatory gene expression.
18-20 Activated NF-κB 
and increased NF-κB DNA binding activity has been demonstrated 
in the inflammed colonic mucosa of patients with IBD.
23-26 These 
findings have suggested that NF-κB may be an effective therapy 
target in treating intestinal inflammation. Previously, EGCG 
blocked NF-κB activation by inhibiting IκB kinase activity in 
intestinal epithelial cell line.
34 And EGCG modulated the pro-
duction of inflammatory cytokines and chemokines in human 
colon cancer cell lines, macrophage cell lines and bone marrow-
derived dendritic cells.
35-40 Moreover, EGCG ameliorated muco-
sal inflammation in mouse experimental colitis models.
41,42 Our 
study showed that EGCG inhibited LPS-induced IκBα degrada-
tion, RelA nuclear translocation and NF-κB DNA binding activ-
ity in BMMs. EGCG inhibited proinflammatory gene expressions 
including cytokines, chemokines, and adhesion molecules in 
BMMs. These results suggest that EGCG exhibits potent anti-
inflammatory effects by modulating proinflammatory gene pro-
ductions via blockade of NF-κB activation. 
MAPKs have been implicated in many physiologic processes, 
including cell proliferation, differentiation, and apoptosis. Three 
major types of MAPKs in mammarian cells are the ERK1/2, 
JNK, and p38 MAPKs.
21,22 Activated MAPKs modulate a number 
of different steps in the inflammatory cascade. These include 
production of pro-inflammatory cytokines, degranulation of 
neutrophils, as well as the expression of important determining 
parameters of colon injury including cyclooxygenase-2 (COX-2) 
and inducible nitric oxide synthase (iNOS).
27-30 Previously, EGCG 
has been shown to inhibit angiogenesis and induce arrest of cell 
cycle and apoptosis in variable cancer cell lines and protected 
oxidative stress-mediated damage which is partly mediated 
by suppression of MAPKs pathway.
43-46 Our study showed that 
EGCG inhibits LPS-induced phosphorylation of ERK1/2, JNK, 
and p38 in BMMs. In addition, an inhibitor of MEK-1/2, U0126 
suppressed the LPS-induced ERK1/2 phosphorylation and proin-
flammatory gene expressions including cytokines, chemokines 
and adhesion molecules in BMMs. These findings are similar 
with those of EGCG treatment. Therefore, these results indicate 
that inhibition of proinflammatory gene expressions by EGCG 
may be caused by inhibition of MAPK signaling pathway in 
BMMs. 
Taken together, EGCG has been shown to modulate NF-κB 
and MAPK signaling pathways in a fashion that controls pro-
inflammatory gene expression, thereby imparting strong anti-
inflammatory effect. Therefore, modulation of these cell signal-
ing pathways by EGCG could contribute to be beneficial in the 
treatment of IBD. 
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